Is IcoSema More Effective Than Insulin Icodec for Type 2 Diabetes?
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.
Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
Is the Dulaglutide Biosimilar LY05008 Equivalent to Trulicity in Chinese Adults With Type 2 Diabetes?
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 equivalent to reference dulaglutide (Trulicity) for HbA1c reduction at 24 weeks. PICO summary and expert commentary.
Does a GPR119 Agonist Help Glucagon Response in Type 1 Diabetes?
A phase 2a crossover trial finds the GPR119 agonist MBX-2982 does not improve glucagon counterregulation in type 1 diabetes, despite target engagement. PICO summary and commentary.
HEC88473 (Dual GLP-1/FGF21 Agonist): First-in-Human Phase 1 Findings
A phase 1 single-ascending-dose first-in-human trial of HEC88473, a dual GLP-1/FGF21 receptor agonist, reporting tolerability and early metabolic signals in healthy and obese adults. PICO summary and expert commentary.
Does SGLT2 Inhibitor Use Modify Oral Semaglutide’s Cardiovascular Benefit in Type 2 Diabetes?
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide's cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
Once-Weekly Insulin Icodec in Type 2 Diabetes: Consistent Across GLP-1RA and SGLT2i Background Therapy
A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.
Does iGlarLixi Improve Early Blood Sugar Control in Asians with Type 2 Diabetes?
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.
REMIND-DM: Design of a Cluster-Randomised Trial of PCI-Report Reminders for Diabetes Discharge Care
REMIND-DM is the protocol and baseline description of a cluster-randomised quality improvement trial testing PCI-report reminders to boost SGLT2 inhibitor and GLP-1RA prescribing after PCI in type 2 diabetes; no outcomes are yet reported. PICO summary and expert commentary.
Trial Protocol: Can Peer-Champion Support Increase SGLT2i and GLP-1RA Prescribing in Primary Care?
A published protocol for a pragmatic cluster-randomized trial testing peer-champion interventions to increase SGLT2i and GLP-1RA prescribing in primary care, reporting design and baseline cohort only with no clinical outcomes yet. PICO summary and expert commentary.